12 results about "Prostate disease" patented technology

The present application relates to the technical field of stem cell medicine, in particular to a mesenchymal stem cell composition for treating prostate diseases and a preparation method and application thereof. The mesenchymal stem cell composition for treating prostate diseases comprises mesenchymal stem cells treated by low oxygen and an anti-inflammatory peptide WYPWMKKHHRRRRRRRRR. The prostate diseases are selected from prostatitis, prostate calcification, sexual function improvement, frequent urination and urgency, etc. The mesenchymal stem cell composition can significantly improve the symptoms of prostate diseases, and the curative effect is remarkable.

The invention discloses a medical biological dressing suppository matrix and a preparation method thereof, and relates to the technical field of suppositories, the medical biological dressing suppository matrix is prepared by taking gelatin, glycerol, polyethylene glycol derivatives and chitosan quaternary ammonium salt as raw materials, the biocompatibility of the suppository matrix is good, and stimulation and anaphylactic reaction cannot be generated on a medication cavity; and after the suppository matrix is dissolved in the cavity, a film with good adhesion can be formed on the mucous membrane of the cavity, so that the released medicine is fully contacted with the focus for a long time, the curative effect and bioavailability of the medicine are improved, and the suppository is suitable for preparing suppositories for treating gynecological diseases, anorectal diseases and prostate diseases.

The invention relates to the technical field of stem cell medicines, in particular to a mesenchymal stem cell composition for treating prostate diseases as well as a preparation method and application of the mesenchymal stem cell composition. The mesenchymal stem cell composition for treating the prostate diseases, disclosed by the invention, is prepared from mesenchymal stem cells subjected to hypoxia treatment and an anti-inflammatory peptide WYPWMKKHRRRRRRRR. The prostate diseases are selected from prostatitis, prostate calcification, sexual function improvement, frequent micturition, urgent micturition and the like. The mesenchymal stem cell composition disclosed by the invention can be used for remarkably improving symptoms of prostate diseases and is remarkable in curative effect.

The purpose of this invention is to establish a single-particle inductively coupled plasma mass spectrometry (ICP-MS) method for analyzing single magnetic microspheres, which can effectively avoid signal fluctuations caused by errors during absolute quantification, achieving stable and accurate quantification of two prostate cancer biomarkers. The principle of this invention is: using... + Fe 58 The frequency signals of isotopes are used to unify the number of magnetic microspheres, and the results are obtained by evaluating the frequency signals of individual magnetic microspheres. + Au 197 and + Pt 194 The intensity distribution, calculated through average intensity or fitted intensity, yields stable analytical results unaffected by changes in the number of magnetic microspheres detected. This is achieved using the intensity distribution on a single magnetic microsphere. + Au 197 and + Pt 194 The linear relationship between intensity and tPSA and fPSA demonstrates that this analytical method enables the simultaneous detection of two prostate cancer biomarkers and can be applied to the simultaneous analysis of the concentrations of the two biomarkers in the serum of patients with prostate disease.

The invention discloses a bispecific antibody-UC-MSCs preparation for targeting prostate diseases as well as preparation and application of the bispecific antibody-UC-MSCs preparation. The preparation comprises a bispecific antibody BsAb-1 and human umbilical cord mesenchymal stem cells (UC-MSCs), the BsAb-1 is formed by connecting an anti-CD105 single-domain antibody, an anti-PSCA single-domain antibody and a flexible peptide linker in series, wherein the amino acid sequence of the BsAb-1 is as shown in SEQ ID NO: 4. According to the preparation, the UC-MSCs are delivered to a prostate focus through the targeting bridge effect of BsAb-1, the focus enrichment amount within 72 hours is increased by 6.3 times compared with that of pure UC-MSCs, and meanwhile retention of non-target organs such as the liver and the spleen is reduced. The preparation can effectively relieve inflammatory response and fibrosis of chronic prostatitis, and the curative effect of the preparation is remarkably superior to that of pure UC-MSCs treatment. Precise targeted treatment of prostate diseases is achieved, the curative effect is remarkably better than that of a traditional stem cell therapy method, and high clinical application value is achieved.

This invention relates to the field of in vitro diagnostics, and particularly to a combined diagnostic kit for prostate diseases. The invention provides reagents including pH, peroxidase, elastase, lecithin bodies, citric acid, zinc, and acid phosphatase under mild reaction conditions, enabling rapid differentiation of inflammatory and non-inflammatory prostatitis, benign prostatic hyperplasia, and non-prostatic genital tract infections using a single test card. Through extensive experimentation, this invention has developed a one-step reaction scheme suitable for the dry chemical determination of acid phosphatase and lecithin bodies in seminal plasma. This method eliminates the need for a stop solution, achieving a one-step reaction under mild conditions that will not cause damage to operators or fully automated instruments. The samples used are seminal plasma or semen, allowing for large sample volumes and easy acquisition, significantly improving diagnostic efficiency for doctors and patient comfort.

The invention relates to the technical field of traditional Chinese medicine, in particular to application of a traditional Chinese medicine composition in preparation of a medicine for treating prostate diseases. The traditional Chinese medicine composition takes prepared rehmannia root and poria cocos as main medicines, can assist spleen transportation and transformation to insulate a source of phlegm and can also remove dampness and turbidity to directly relieve dysuria, meanwhile, the dampness removing property of the traditional Chinese medicine composition can restrict greasy taste of the prepared rehmannia root, and the effect of treating prostate diseases is achieved. Cistanche deserticola, astragalus mongholicus and ginseng are used as auxiliary medicines to tonify yin and yang and provide motive power for lower-jiao gasification, astragalus mongholicus and ginseng greatly tonify primordial qi, invigorate the spleen, benefit qi and strengthen the postnatal root, and maca is used as auxiliary medicines to enhance the overall function. According to the traditional Chinese medicine composition, all the medicines are compatible to jointly achieve the effects of tonifying kidney and spleen to consolidate foundation, promoting diuresis and reducing phlegm, and activating blood circulation and eliminating diseases to treat symptoms, the prostate volume is effectively reduced, the urination symptom is improved and the purpose of treating prostatic hyperplasia is achieved by improving the lower-jiao gasification function, promoting water metabolism and softening and dissipating prostate phlegm and blood stasis diseases, and the traditional Chinese medicine composition attacks pathogens without hurting vital energy, tonifies deficiency without lingering pathogens and has no toxic or side effect. And specimens are considered.

The invention discloses a preparation method and application of prostate lineage progenitor cells obtained by multi-stage induction of human induced pluripotent stem cells. The method comprises the following steps: sequentially inducing to form a definitive endoderm, a posterior intestinal urogenital sinus progenitor cell and a prostate progenitor cell, and at the third stage, adopting a collaborative regulation system in which LDN193189 and CHIR99021 are simultaneously added, so that the lineage specialization efficiency and the cell amplification capacity are remarkably improved. And further sorting through a CD49f high-expression membrane marker combination, a Trop2 positive membrane marker combination, a CD26 low-expression membrane marker combination and a CD117 negative membrane marker combination, so that a cell population with high purity, low heterogeneity and immunoregulation potential can be obtained. The cell can reconstruct a gland structure and secrete prostate specific protein in an animal model, and meanwhile, the inflammatory microenvironment is improved through immune tolerance related pathways. The process can realize batch production and maintain product activity and stability, and is suitable for treating chronic prostatitis, postoperative tissue defect, dysfunction and other diseases.

This application discloses a method and related products for analyzing drug safety and efficacy based on target trial simulation. The method preprocesses clinical data from patients with prostate disease to obtain standardized data; then, it simulates a target trial on the standardized data according to preset conditions to determine the simulation trial dataset and analysis parameter table. The simulation trial dataset is a set of standardized data used to simulate clinical trial analysis; the analysis parameter table is a set of parameter configurations recording the preset conditions used in the target trial simulation process; the preset conditions include inclusion / exclusion criteria, treatment grouping rules, follow-up rules, and bias control strategies; finally, it performs drug safety and efficacy analysis on the simulation trial dataset and analysis parameter table to obtain the drug safety and efficacy analysis results. This avoids the time-consuming, labor-intensive, and difficult-to-conduct aspects of traditional clinical trials, achieving high efficiency and low cost while providing relatively rigorous and reliable results to support the needs of rapid clinical decision-making.

The disclosure relates to compositions and methods for rAAV-mediated delivery of a transgene to a subject. In some embodiments, the rAAV transduces the prostate tissue of a subject. In some embodiments, the methods are useful for treatment of prostate disease (e.g., prostatitis, BPH, prostate cancer).

The present invention relates to the use of a therapeutically effective amount of an aqueous extract of Drymis winteri var. Chilensis for the manufacture of a natural remedy for the treatment or prevention of prostate problems such as prostatitis, benign prostatic hyperplasia or malignant prostate carcinomas, which is to be administered orally or nasally. and a procedure for treating problems of the prostate such as prostatitis, benign prostatic hyperplasia or malignant prostate cancer in a patient, wherein the procedure includes the following: - Administration of the natural remedy produced from the aqueous extract according to the invention to the patient for the treatment of prostate problems such as prostatitis, benign prostatic hyperplasia or malignant prostate carcinomas for a period sufficient to treat prostate problems such as prostatitis, benign prostatic hyperplasia or malignant prostate carcinomas.

According to the application of the flibaserin and the derivative thereof in preparing the medicine for resisting the prostate diseases, the flibaserin serves as a treatment medicine, proliferation of prostate cancer cells can be inhibited, growth of in-vivo tumors can be inhibited, on the premise of low toxic and side effects, the progress of castration-resistant prostate cancer can be relieved, and the prostate diseases can be prevented. Prostatic hyperplasia and prostatic hyperplasia are reduced; the method plays an important role in prolonging the lifetime of a patient and slowing down proliferation, migration and invasion of diseases.